H. Lundbeck A/S and Neurim Pharmaceuticals Ltd. announced that Lundbeck has obtained expanded exclusive rights to commercialize Circadin® in Asia, Latin America and other major markets such as Australia and Turkey. Following regulatory filing and approval Lundbeck expects to market Circadin® in the first markets outside of Europe in 2009.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments